Lysosome-targeting agents in cancer therapy

Guido Kroemer; Lorenzo Galluzzi

doi:10.18632/oncotarget.21451

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspective: Autophagy:

Lysosome-targeting agents in cancer therapy

Guido Kroemer _ and Lorenzo Galluzzi

PDF | HTML | How to cite

Oncotarget. 2017; 8:112168-112169. https://doi.org/10.18632/oncotarget.21451

Metrics: PDF 1514 views | HTML 2024 views | ?

Abstract

Guido Kroemer1,2,3,4,5,6,7 and Lorenzo Galluzzi1,8,9

1 Université Paris Descartes/Paris V, Paris, France

2 Université Pierre et Marie Curie/Paris VI, Paris, France

3 Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France

4 INSERM, U1138, Paris, France

5 Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France

6 Department of Women’s and Children’s Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

7 Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP, Paris, France

8 Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA

9 Sandra and Edward Meyer Cancer Center, New York, NY, USA

Correspondence to:

Guido Kroemer, email:

Lorenzo Galluzzi, email:

Keywords: anticancer immunosurveillance, autophagy, chemotherapy, chloroquine, hydroxychloroquine

Received: August 31, 2017 Accepted: September 16, 2017 Published: October 03, 2017

Abstract

Despite considerable efforts from multiple laboratories worldwide, highly specific inhibitors of autophagy for clinical use are not yet available. Lysosomal inhibitors are being employed instead, in spite of multiple limitations that are summarized herein.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21451

Publication Alerts

Research Perspective: Autophagy:

Lysosome-targeting agents in cancer therapy

Abstract